Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on November 20, 2025, and filed on November 21, 2025. The transaction was executed through BNP Paribas SA as part of GSK's existing share buyback programme, which was announced on September 30, 2025. The purchased shares are held as Treasury shares.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases rather than full-period financial results. Key metrics for the November 20, 2025 transaction include:
- Shares Purchased: 360,000 ordinary shares.
- Price Range: Lowest price paid was 1,755.00 GBp; highest price paid was 1,783.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,766.45 GBp.
- Trading Venues: Purchases were distributed across BATE (60,026 shares), CHIX (109,421 shares), and XLON (190,553 shares).
Since the programme's inception on September 30, 2025, GSK has purchased a total of 9,958,000 ordinary shares. Following this transaction, the company holds 235,422,844 ordinary shares in treasury, representing 5.77% of voting rights. The total number of ordinary shares in issue (excluding treasury shares) is 4,080,008,266.
Material Changes and Programme Status
The filing confirms the continuation of the non-discretionary agreement entered into with the broker. There are no material changes to the company's financial position reported in this specific filing other than the reduction in shares outstanding and the increase in treasury holdings. The filing does not provide data on revenue, profit, cash flow, or debt levels, as it is a transaction report rather than a financial results statement.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Investors are directed to the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and the Q3 Results for 2025 for a detailed discussion of these risks. No new guidance or specific management commentary regarding future financial performance is provided in this document.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,080,008,266) against the company's latest capitalization table to confirm the denominator for voting rights calculations.
- Confirm the cumulative buyback volume (9,958,000 shares since Sept 30, 2025) against previous 6-K filings to track programme progress.
- Note that treasury shares (235,422,844) represent 5.77% of voting rights, which may impact dilution calculations for future issuances.
- Review the specific transaction prices (1,755.00p - 1,783.00p) to assess the cost basis of the recent repurchase relative to market conditions on November 20, 2025.